Radiopharmaceutical Trials in Latin America: Logistics That Make or Break Your First Patient In

Radiopharmaceutical clinical trials behave differently from most other clinical programs. The “product” is not just a vial—it is a time-sensitive system that includes isotope production, radiolabeling, quality control (QC), packaging, cross-border movement, and last-mile delivery to the imaging suite or treatment room. The most successful programs design these constraints into the protocol from day one.

Across Latin America, sponsors can unlock faster activation and access to experienced nuclear medicine teams, but they also face logistical realities: variable availability of isotopes, airport cargo limitations, customs clearance variability, and the physics of radioactive decay. A 2026 Pharmaphorum analysis emphasizes that short half-lives require carefully managed distribution, compliance with strict international regulations, specialized packaging, and in some cases decentralized or local radiolabeling rather than centralized manufacturing.

This article outlines a logistics-first playbook for radiopharmaceutical trials in Latin America, focusing on practical steps that protect schedule, quality, and patient safety without disclosing confidential sponsor details.

Start with physics: half-life drives everything

The logistics challenge scales with how quickly your isotope loses usable activity. Pharmaphorum highlights that some isotopes used in radiotherapeutics have very different half-lives, including approximately 6.7 days for Lu-177 and about 10.6 hours for Pb-212. When half-life is short, “time in transit” becomes a clinical performance variable, not merely an operational cost.

Implication: your trial design must specify not only dose and administration, but also supply chain constraints such as maximum transport duration, acceptable activity range at administration, and contingencies when shipments miss the window.

Design the supply chain as part of the protocol

In radiopharma, supply chain and protocol are inseparable. The Pharmaphorum article notes that shipping requires compliance with strict international regulations and specialized packaging. Sponsors should treat packaging qualification, lane qualification, and customs planning as protocol-enabling activities.

• Define the chain of custody: who releases the batch, who transports it, and who receives it at the site.
• Define time stamps: end of synthesis, QC release, handoff to carrier, arrival at airport, customs release, receipt at site, administration time.
• Define acceptance criteria: activity at administration, sterility assurance approach, and temperature/shielding requirements.

Common pitfall: a protocol that assumes a “normal” drug supply chain will often fail on the first shipment because radiopharma realities (lane availability, airline acceptance, customs timing) were not operationalized.

Import and transport compliance: plan lead times early

Cross-border movement of radioactive materials is governed by multiple layers of regulation. Even outside Latin America, the U.S. Department of Transportation’s 49 CFR §173.476 illustrates the compliance mindset regulators expect: offerors must maintain a safety analysis and documentation of tests demonstrating compliance, and certificate requests may need to be received at least 90 days before the requested effective date. The details differ by jurisdiction, but the principle is consistent—radiopharma transport is a regulated process with non-trivial lead times.

Practical takeaway for LATAM trials: build an “import and transport readiness calendar” that starts months before first patient in. If you wait until sites are activated to address permits and transport documentation, your trial will be delayed even if the science is ready.

Decentralized radiolabeling: when local production beats centralization

One of the most important insights from Pharmaphorum is that short-half-life isotopes can force local radiolabeling. The article explains that while longer half-life isotopes can be labeled in centralized facilities, Pb-212’s shorter half-life necessitates local radiolabeling and therefore a wider geographic footprint. This is a strategic decision: do you build a hub-and-spoke network, partner with regional capabilities, or choose an isotope/asset combination that is more forgiving for your operational footprint?

• Hub-and-spoke model: install generator or labeling capability in a regional hub and distribute doses to nearby sites.
• Site-embedded model: enable radiolabeling at select high-capability hospitals.
• Hybrid model: start with one hub for early-phase feasibility, then expand regionally as you scale enrollment.

Key decision criterion: the relationship between half-life, flight schedules, customs predictability, and on-site capacity to release product to patients.

Operational playbook: a 10-point readiness checklist

• 1) Lane qualification: choose airports and carriers that routinely accept radioactive cargo and can document handling.
• 2) Packaging validation: confirm shielding, labeling, and any required temperature control under realistic transit times.
• 3) QC release plan: clarify which tests are performed before shipment vs. at/near site, and how results are documented.
• 4) Customs “fast track” alignment: prepare documentation so the shipment’s purpose and classification are unambiguous.
• 5) Missed-window contingency: define what happens if activity is below threshold at arrival.
• 6) Scheduling discipline: align patient visits, imaging slots, and dosing windows to inbound shipment timing.
• 7) Training: ensure site staff understand receipt, storage, radiation safety basics, and administration workflows.
• 8) Data capture: capture time stamps and activity measurements as structured data for operational learning.
• 9) Vendor oversight: manage carriers and depots like critical clinical vendors, not like routine couriers.
• 10) Scale strategy: expand to new countries only after proving repeatable shipment-to-administration performance.

FAQ

1) What is the biggest logistics risk in radiopharmaceutical clinical trials?

For many programs, the biggest risk is the mismatch between isotope half-life and real-world transit time. If the product loses activity before administration, schedule and enrollment are immediately impacted.

2) When is local radiolabeling necessary?

Pharmaphorum notes that for very short half-life isotopes such as Pb-212 (about 10.6 hours), local radiolabeling may be necessary because centralized labeling can be incompatible with transit time and decay.

3) How should sponsors plan for regulatory transport requirements?

Start early and assume non-trivial lead times. Regulations like 49 CFR §173.476 show that authorities expect documented safety analyses and, in some cases, certificate requests planned months in advance. Use that mindset to build a transport-ready process tailored to each participating LATAM jurisdiction.

Educational content only. Sponsors should consult qualified radiopharmaceutical manufacturing, logistics, and regulatory experts for trial-specific requirements.